Citigroup
HZNP

Citigroup’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Citigroup’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-350,151
Closed -$40.5M – 5971
2023
Q3 		$40.5M Buy
350,151
+111,940
+47% +$12M 0.03% 504
2023
Q2 		$24.5M Sell
238,211
-10,581
-4% -$1.12M 0.02% 729
2023
Q1 		$27.2M Buy
248,792
+11,698
+5% +$1.29M 0.02% 664
2022
Q4 		$27M Sell
237,094
-41,720
-15% -$3.47M 0.02% 654
2022
Q3 		$17.3M Buy
278,814
+74,554
+36% +$5.21M 0.01% 858
2022
Q2 		$16.3M Buy
204,260
+89,603
+78% +$8.49M 0.01% 896
2022
Q1 		$12.1M Sell
114,657
-5,311
-4% -$518K 0.01% 1207
2021
Q4 		$12.9M Sell
119,968
-267,385
-69% -$29.2M 0.01% 1242
2021
Q3 		$42.4M Buy
387,353
+38,978
+11% +$4.05M 0.03% 610
2021
Q2 		$32.6M Buy
348,375
+157,676
+83% +$14.5M 0.02% 734
2021
Q1 		$17.6M Buy
190,699
+38,392
+25% +$3.24M 0.01% 1024
2020
Q4 		$11.1M Buy
152,307
+12,584
+9% +$935K 0.01% 1468
2020
Q3 		$10.9M Sell
139,723
-72,807
-34% -$5.01M 0.01% 1308
2020
Q2 		$11.8M Buy
212,530
+162,464
+324% +$6.95M 0.01% 1182
2020
Q1 		$1.48M Buy
50,066
+248
+0.5% +$8.39K ﹤0.01% 2786
2019
Q4 		$1.8M Sell
49,818
-10,482
-17% -$321K ﹤0.01% 3109
2019
Q3 		$1.64M Sell
60,300
-22,359
-27% -$578K ﹤0.01% 3086
2019
Q2 		$1.99M Sell
82,659
-56,493
-41% -$1.43M ﹤0.01% 2864
2019
Q1 		$3.68M Sell
139,152
-47,249
-25% -$1.12M ﹤0.01% 2054
2018
Q4 		$3.64M Buy
186,401
+124,513
+201% +$2.44M ﹤0.01% 2119
2018
Q3 		$1.21M Buy
61,888
+21,315
+53% +$405K ﹤0.01% 3273
2018
Q2 		$672K Sell
40,573
-240,228
-86% -$3.66M ﹤0.01% 3780
2018
Q1 		$3.99M Sell
280,801
-277,830
-50% -$4.1M ﹤0.01% 1975
2017
Q4 		$8.16M Sell
558,631
-792,503
-59% -$11.1M 0.01% 1435
2017
Q3 		$17.1M Sell
1,351,134
-1,232,717
-48% -$15.7M 0.01% 873
2017
Q2 		$30.7M Buy
2,583,851
+2,425,818
+1,535% +$30.2M 0.03% 559
2017
Q1 		$2.33M Sell
158,033
-58,721
-27% -$951K ﹤0.01% 2328
2016
Q4 		$3.51M Buy
216,754
+146,773
+210% +$2.66M ﹤0.01% 2255
2016
Q3 		$1.27M Sell
69,981
-2,051
-3% -$40.1K ﹤0.01% 2960
2016
Q2 		$1.19M Buy
72,032
+1,838
+3% +$29.7K ﹤0.01% 2788
2016
Q1 		$1.16M Sell
70,194
-33,455
-32% -$585K ﹤0.01% 3156
2015
Q4 		$2.25M Buy
103,649
+56,450
+120% +$1.1M ﹤0.01% 2400
2015
Q3 		$935K Sell
47,199
-18,431
-28% -$582K ﹤0.01% 3150
2015
Q2 		$2.28M Buy
65,630
+19,596
+43% +$598K ﹤0.01% 2403
2015
Q1 		$1.2M Buy
46,034
+25,169
+121% +$461K ﹤0.01% 2943
2014
Q4 		$269K Buy
20,865
+14,819
+245% +$185K ﹤0.01% 4446
2014
Q3 		$75K Buy
6,046
+3,780
+167% +$43.9K ﹤0.01% 4998
2014
Q2 		$35K Sell
2,266
-19,376
-90% -$277K ﹤0.01% 5428
2014
Q1 		$327K Sell
21,642
-11,818
-35% -$133K ﹤0.01% 3877
2013
Q4 		$256K Buy
33,460
+24,217
+262% +$131K ﹤0.01% 4444
2013
Q3 		$31K Sell
9,243
-2,491
-21% -$6.57K ﹤0.01% 5625
2013
Q2 		$29K Buy
+11,734
New +$28.2K ﹤0.01% 5659

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citigroup's HZNP Position: Q4 2023 in Review

Citigroup sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 350,151 shares — an estimated $40.5M sold.

Citigroup first reported a position in HZNP in Q2 2013 and held it in 42 quarters. The position peaked at $42.4M in Q3 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Citigroup reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Citigroup sold 350,151 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $40.5M.
  • Citigroup first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 42 quarters.
  • Citigroup's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $42.4M in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Citigroup's 13F filing for Q4 2023, filed 9 Feb 2024.